Home  Contact Us
  Follow Us On:
 
Search:
Advertising Advertising Free Newsletter Free E-Newsletter
NEWS

Pfizer's new Covid-19 treatment drug is included into medical insurance
Published on: 2022-04-02
Share to
User Rating: / 0
PoorBest 

Since more than 20,000 boxes of drugs entered China on March 17, Pfizer's new coronavirus treatment drug "Nimatevir/Ritonavir Tablets" (Paxlovid) has been distributed to Jilin, Shanghai, Guangdong, Fujian, Jiangxi, at least 8 provinces including Shandong, Zhejiang and Guangxi are on the front line of clinical treatment of new crowns. Several experts in the treatment of new crown patients said: "New crown antiviral drugs should be used early in the course of the disease, focusing on patients with high-risk factors and a tendency to become severely ill."
 

According to the data, Paxlovid is an oral small-molecule novel coronavirus treatment drug for the treatment of mild to moderate adult patients with novel coronavirus with high risk factors for progression to severe disease. Published clinical trial results showed that taking the drug orally reduced the risk of hospitalization and death by 89 percent.
 

In addition to Paxlovid, another domestically-developed monoclonal antibody in China has not yet entered the substantive sales stage, but its safety and efficacy have been supported by certain data. In terms of payment, the above two drugs will be "paid by the medical insurance department according to regulations".
 

新冠治疗新药临时纳入天津医保!

近日,天津市医疗保障局发布通知,自2022年3月14日起,新冠参保患者使用奈玛特韦片/利托那韦片组合包装,临时纳入医保支付范围,最高支付标准联动天津市医药采购平台挂网价格,按甲类药品支付。

Comments (0)Add Comment

Write comment

security code
Write the displayed characters


busy
    Subscription    |     Advertising    |     Contact Us    |
Address: Magnetic Plaza, Building A4, 6th Floor, Binshui Xi Dao.
Nankai District. 300381 TIANJIN. PR CHINA
Tel: +86 22 23917700
E-mail: webmaster@businesstianjin.com
Copyright 2022 BusinessTianjin.com. All rights reserved.